Endovascular Engineering Raises $80M for Thrombectomy

Endovascular Engineering, known as E2, raised $80 million to bring its mechanical thrombectomy platform to market for pulmonary embolism. The company said the financing will help it scale its commercial organization while continuing investment in R&D and operations.

E2 received FDA clearance in late 2025 for the Hēlo thrombectomy system to remove clots from pulmonary arteries and veins, intended for use in the peripheral vasculature. The Series C round was co-led by Norwest and Gilde Healthcare, with additional participation from Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, and M&L Healthcare Investments, plus undisclosed existing investors and a new strategic investor.

E2 previously raised a $42 million Series B round.